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Abstract 
The purpose of this study was to investigate cartilage repair of in vitro lesion models using human 
bone marrow mesenchymal stromal cells (hBMSCs) with different collagen (Col) scaffolds. 
Lesions were made in human cartilage biopsies. Injured samples were pre-treated with interleukin 
1β (IL1β) for 24 h; also, samples were not pre-treated. hBMSCs were seeded on different types of 
collagen scaffolds. The resulting constructs were placed into the lesions, and the biopsies were 
cultured for 2 months in chondrogenic medium.  
Using the modified ICRSII scale, neotissues from the different scaffolds showed ICRS II overall 
assessment scores ranging from 50% (fibrocartilage) to 100% (hyaline cartilage), except for the Col 
I +Col II +HS constructs (fibrocartilage/hyaline cartilage, 73%). Data showed that hBMSCs cultured 
only on Col I +Col II +HS scaffolds displayed a chondrocyte-like morphology and cartilage-like 
matrix close to native cartilage. Furthermore, IL1β  pre-treated biopsies decreased capacity for 
repair by hBMSCs and decreased levels of chondrogenic phenotype of human cartilage lesions. 
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Introduction 
It is widely accepted that three-dimensional (3D) 
in vitro cultures simulate the in vivo situation better 
than two-dimensional ones. Although micromass 
culture is considered a useful tool for studies of 
chondrogenesis, it is not suitable for cell therapy [1]. 
Scaffolds can, however, provide an appropriate 3D 
environment for cell viability and proliferation, cell 
differentiation and maintenance of a specific 
phenotype [2].  
Tissue Engineering using biodegradable 
scaffolds, cells and cell factors has evolved into a 
multidisciplinary field with an aim to develop 
biological substitutes with biochemical, structural, 
morphological and functional properties similar to 
native cartilage for subsequent use for in vivo 
treatment [3]. The most important issue in Tissue 
Engineering is the selection of cell type and optimal 
scaffold.  
Most studies have tested growth and 
differentiation of cells on various scaffolds but have 
not placed the constructs inside a native cartilage 
environment or taken the host tissue into account [4]. 
In vitro testing is easier than in vivo testing for 
obtaining standardized and quantifiable information 
about cell cytotoxicity, proliferation and 
differentiation capacity [5]. This model allows us to 
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analyze human cartilage samples from a single donor 
using different study variables and to test different 
constructs in an in vitro native environment. In our 
study, this model was used to test the repair capacity 
of different constructs.  
Materials and Methods 
Isolation and culture of bone marrow stromal 
cells 
Each donor in the study gave informed consent 
according to the guidelines of the local ethics 
committee and principles of Declaration of Helsinki. 
This study was approved by the Ethics Committee of 
Clinical Investigation of Galicia (Santiago de 
Compostela, Spain). 
Bone marrow cells were obtained from three hip 
fracture patients who underwent total hip 
replacement, as previously described [6]. Cells were 
extracted by washing the bone marrow with culture 
medium: Dulbecco´s Modified Eagle´s Medium 
(DMEM; Lonza, Spain) with 20% foetal bovine serum 
(LabClinics, Spain). The isolated cells were cultured in 
a 5% humidified CO2 atmosphere at 37ºC. The 
resultant cell suspension was cultured and expanded. 
We previously confirmed by characterization [6] that 
cells obtained by this method are hBMSCs.   
Scaffolds 
Different Col scaffolds (Opocrin S.p.A., Modena, 
Italy) had been previously tested by our group [6, 7]. 
From those, scaffolds producing better chondrogenic 
hBMSC phenotypes, including type I collagen (Col I), 
Col I and heparan sulfate (Col I+HS), Col I and type II 
collagen (Col II) and HS (Col I+Col II+HS) and Col I 
and Col II and chondroitin sulfate (Col I+Col II+CHS) 
were selected. The hBMSCs were cultured on the 
surface of 4 mm-diameter sponges and incubated for 1 
h at 37ºC. These constructs were used for the in vitro 
lesion model using chondrogenic medium: hMSC 
Chondrogenic Differentiation Bulletkit medium 
(Lonza, Spain) with 10ng/ml of human transforming 
growth factor β-3 (TGFβ-3, Prospec-Tany Technogene 
Ltd., Israel). 
In vitro lesion model 
Cartilage samples were obtained from three 
patients who underwent total hip or knee 
replacement because of fracture or osteoarthritis 
(OA). The cartilage was sliced with a scalpel and 6mm 
biopsies were obtained using disposable biopsy 
punches (Kai Medical, Germany).   
3 mm-Diameter lesions were made in human 
cartilage biopsies using a dental drill (Gebr. Brasseler 
Gmbh & Co. KQ, Germany) with a rotor (EWL K9, 
Germany). Over a two-month period, two 
experiments were performed: 
1) Non-IL1β Group: 2x105 cells were seeded on 
scaffolds. These constructs were placed into the lesion 
and chondrogenic medium was added. The medium 
was changed every 3-4 days. 
2) IL1β Group: Cartilage biopsies with lesions 
were pre-treated with 10ng/ml of IL1β (Sigma, USA) 
for 24 hours. 2x105 cells were seeded on scaffolds, the 
resulting sponge-constructs were introduced into the 
lesion and chondrogenic medium was added. The 
medium was changed every 3-4 days.  
Following controls were included: defect 
without constructs, defect with scaffolds and without 
cells, and native cartilage without defect (Figure S1).  
Histological analysis 
The resulting neotissue was evaluated 
histochemically using 4 µm-thick deparaffinized 
sections. These sections were then stained with 
hematoxylin and eosin (HE), and stained for collagen 
and proteoglycans (PGs) with Masson's trichrome 
(MT) or Safranin O (SO), respectively. The stained 
sections were examined using an optical microscope 
(Olympus BX61, USA) equipped with a digital camera 
(Olympus DP70, USA). Quantitative analyses of the 
SO staining were measured using ImageJ 1.48v 
(National Institutes of Health, Bethesda, USA). After the 
colour substraction of non-stained areas, the 
percentage of metachromatic areas was measured and 
expressed as mean±standard error. 
To assess the quality of cartilage repair, the ICRS 
II histological scoring system [8] was used with some 
modifications to adapt it for analysis of in vitro 
cartilage repair. The neotissues formed were scored 
by three blind observers. Our modified score system 
comprised 7 out of the 14 parameters: “cell 
morphology” and “chondrocyte clustering” as well as 
“surface architecture” and the “basal integration” of 
the neotissue formed were observed by the HE 
staining; “tissue morphology” was assessed by 
analyzing the collagen fiber distribution with MT 
staining;  the parameter to evaluate PG content was 
“matrix staining”, which was assessed using SO 
staining; and, the “overall assessment” was the 
statistical mean of the values for all 6 parameters 
analyzed.   
Further immunohistochemical analysis of Col I, 
Col II and aggrecan (Agg) was performed in samples 
with highest ICRS II score.  
Results  
Controls and Non-IL1β model 
Control constructs without cells did not show 
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presence of neotissue formation and the scaffolds 
were not degraded (Figure S1, Ctrl w/o cells). 
Self-repair did not occur in the negative control 
(Figure S1, control lesion). In the Non-IL1β model, 
histochemistry after two months revealed that cells 
seeded on all scaffolds filled almost 100% of the lesion 
and that neotissues were integrated with the border of 
the lesion (Figure 1, H-E Non-IL). Scaffolds were 
almost fully degraded in this model, except the Col 
I+HS scaffold, and cellular density in all the grafts 
was higher (Figure 1, H-E Non-IL) than that in the 
native cartilage (Figure S1, positive control). Spindle- 
and round-shaped cell morphology was found in all 
neotissues.  
Staining with MT showed the presence of Col in 
the ECM of all the constructs (Figure 1, H-E Non-IL), 
that was observably more homogeneous in the tissues 
of the Col I+Col II+HS constructs. The presence of 
PGs detected by SO staining (Figure 1, H-E Non-IL) 
was more metachromatic in the Col I+Col II+HS 
constructs (52.426±4.877) than in Col I (5.107±3.337), 
Col I+HS (23.406±6.189) and Col I+Col II+CHS 
(32.722±8.781) constructs.  
 
 
Figure 1. Histology of repair in human cartilage non interleukin- 1β-treated lesions (Non-IL) and IL1β-treated lesions (IL). Hematoxylin-eosin (HE), 
Safranin O (SO) and Masson’s Thricrome (MT) staining of the models. Scale bar 100µm (smaller images 200 µm). Col I: type I collagen; Col II: type II collagen; HS: 
heparan sulfate; CHS: chondroitin sulfate. 
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Figure 2. Histology and immunohistochemistry of repair obtained using type I and II collagen and heparan sulfate scaffolds (Col I+Col II+HS), in 
non-interleukin-1β-treated lesions. Images of Safranin O (SO) and Masson’s Thricrome (MT) staining, and type I (Col I) and II (Col II) collagen and aggrecan (Agg) 
immunostaining performed on the neotissues formed on Col I+Col II+HS scaffolds in the Non-IL model. Col and Agg immunostaining were counterstaining with 
hematoxylin-eosin. Scale bar 100µm. 
 
Table 1. Assessment of quality of repair in human cartilage non interleukin- 1β-treated lesions (Non-IL) and IL1β-treated lesions (IL). 
International Cartilage Repair Society II (ICRS II) scale values for different scaffolds in the Non-IL1β-treated and IL1β -treated model. Our 
modified scoring system comprises 7 of the 14 original parameters.  
Parameter  Col I  
(Non-IL)  
Col I (IL)  Col I +HS (Non-IL)  Col I  
+HS  
(IL)  
Col I + 
Col II  
+HS  
(Non-IL)  
Col I + 
Col II  
+HS (IL)  
Col I  
+Col II +CHS  
(Non-IL)  
Col I  
+Col II +CHS  
(IL)  
Tissue morphology  30  5  35  30  50  20  35  20  
Matrix staining  0  0  5  0  50  5  15  0  
Cell morphology  15  0  5  25  70  40  80  40  
Chondrocyte 
clustering  
100  100  100  100  100  100  100  100  
Surface architecture  90  80  80  90  90  90  40  50  
Integration  30  5  60  50  80  65  10  50  
Overall assessment  44%  31%  47%  49%  73%  53%  46%  43%  
Col I: type I collagen; Col II: type II collagen; HS: heparan sulfate; CHS: chondroitin sulfat. 
 
 
 
By macroscopic ICRS II assessment of the Non-IL 
model, the repair score was between 44% and 47%, or 
fibrocartilage, for Col I, Col I+Col II+CHS and Col 
I+HS scaffolds. Col I+Col II+HS scaffolds showed a 
chondrogenic phenotype, 73%, or mixed 
firbrocartilage and hyaline cartilage on the ICRS II 
scale. This was confirmed by histological and 
immunohistochemical analysis that showed the 
presence of PGs and Col, being positive for Col II and 
Agg (Figure 2).  
IL1β-treated model 
In the IL1β model, HE staining showed neotissue 
formation within the lesion with fewer rounded cells 
than in the Non-IL1β model (Figure 1, H-E IL). The 
presence of PGs detected by SO staining (Figure 1, 
H-E IL) was more metachromatic in the Col I+Col 
II+CHS constructs (23.228±1.704) than in Col I 
(5.738±1.283), Col I+HS (5.107±2.435) and Col I+Col 
II+HS (20.973±6.849) constructs. These morphological 
changes with the loss of ECM components observed 
by SO and MT staining resulted in lowering of the 
ICRS II scores except those for the Col I+HS and Col 
I+Col II+CHS constructs (49%-43%, respectively) 
(Table 1).  
Discussion 
This model supposes an improvement compared 
with other 3D in vitro models.  
Because cell phenotype and extracellular matrix 
(ECM) vary with cartilage depth [9], constructs, once 
implanted, are influenced by the native cell 
metabolism of each zone [10].  
We found that cellular density in all the grafts 
was higher than in the native cartilage and, 
flattened-like undifferentiated cells were observed in 
all the scaffolds. The presence of undifferentiated 
hBMSCs or chondrocyte-like cells without zonal 
organization may be advantageous for Cartilage 
Engineering because immature tissue is capable of 
maturing when implanted in the joint [4]. 
Col I+Col II+HS scaffolds showed a 
fibrocartilage/hyaline cartilage phenotype, using the 
ICRS II scale. These results are similar to those 
obtained in a clinical study following microfracture 
treatment [11].  
Chondrocytes implanted into focal or OA joint 
lesions were susceptible to native inflammation. 
Furthermore, problems with mechanics in OA and 
eventual loss of integrity, functionality and, long-term 
neotissue viability could be compromised [12]. Khan 
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et al. found that a single short catabolic pulse of IL1β 
followed by post-culture anabolic conditions is 
sufficient to generate mechanically robust, integrative 
cartilage repair [13]. That is why secondly, an in vitro 
lesion model in which explants were pre-treated with 
IL1β before culture in chondrogenic medium was 
developed.  
Different studies have shown that in vivo 
infiltration of IL1β into the joints results in 
degradation of Col and PGs from the chondrocyte 
ECM [13]. In our study, constructs showed lower 
amounts of PGs and less rounded cells after IL1β 
treatment than without treatment, except in CHS 
scaffolds. Scaffolds composed of CHS have been 
described as having better anti-inflammatory 
properties [14].    
Regarding to the ICRS II scale, it was 
demonstrated lower inter- and intra-reader variability 
compared with other traditional scales. The overall 
assessment and matrix staining scores had the best 
correlation coefficients for inter- and intra-reader 
variability [8]. However, there are limitations of this 
study to take into account. It is necessary to consider 
any disadvantage of assessing the quality of repair in 
the in vitro developed models using the ICRS II scale, 
which was originally designed to evaluate in vivo 
osteochondral repair. ICRS II [8] was developed 
comprising 14 criteria: tissue morphology, matrix 
staining, cell morphology, chondrocyte clustering, 
surface architecture, basal integration, tidemark 
formation, subchondral bone fibrosis, inflammation, 
abnormal calcification, vascularization, surface 
assessment, mid/deep zone assessment and overall 
assessment. However, we focus on the assessment of 7 
out of 14, which were related to chondrocyte 
phenotype and tissue structure. The assessment of the 
other 7 parameters was not possible in our developed 
model (tidemark formation, subchondral bone 
fibrosis, inflammation, abnormal calcification, 
vascularization, surface assessment and mid/deep 
zone assessment).  
It is also relevant to point out that lack of 
mechanical stimuli negatively influences the quality 
of the neotissue formed. It is well known that 
continuous passive movement was shown to 
stimulate the repair of focal lesions with a neotissue 
similar to hyaline cartilage [9] and movement and 
loading in the joint were demonstrated to be essential 
for development and maintenance of normal cartilage 
structure [15]. The duration of our study was only two 
months, which is less time than that described in the 
literature. Because cartilage repair is a slow process, 
mathematical models have predicted that more than 
18 months would be required to obtain complete 
cartilage maturation in vivo [5]. In vitro culture for long 
periods of time increases the risk of culture 
contamination and cartilage degradation [3]. 
However, our group had previously tested these 
two-month-culture-models without culture 
contamination or tissue degradation [16].  
In conclusion, in an in vitro model using hBMSCs 
cultured on a Col I +Col II +HS scaffold displayed 
higher overall human cartilage lesion repair 
assessment than those of the other scaffolds. The 
capacity for repair by hBMSCs and the levels of 
construct chondrogenic phenotype of human cartilage 
lesions are lessened by pretreatment with IL1β. 
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